Correspondence 0001193125-24-281271 from Prime Medicine, Inc. (PRME) (CIK 0001894562) (PRME)
Prime Medicine, Inc. (PRME) (CIK 0001894562)
Date: Dec. 18, 2024 · CIK: 0001894562 · Accession: 0001193125-24-281271
AI Filing Summary & Sentiment
File numbers found in text: 333-283780
Letter
Re: Prime Medicine, Inc.
VIA EDGAR
December 18, 2024
United States Securities and Exchange Commission
Office of Life Sciences
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Acceleration Request for Registration Statement on Form S-3
Filed December 13, 2024
File No. 333-283780
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Prime Medicine, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to December 20, 2024, at 4:01 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP, by calling Marishka DeToy at (617) 570-1926. If you have any questions regarding this request, please contact Marishka DeToy of Goodwin Procter LLP at (617) 570-1926.
Sincerely,
PRIME MEDICINE, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP VIA EDGAR December 18, 2024 United States Securities and Exchange Commission Office of Life Sciences Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Prime Medicine, Inc. Acceleration Request for Registration Statement on Form S-3 Filed December 13, 2024 File No. 333-283780 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Prime Medicine, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to December 20, 2024, at 4:01 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP, by calling Marishka DeToy at (617) 570-1926. If you have any questions regarding this request, please contact Marishka DeToy of Goodwin Procter LLP at (617) 570-1926. Sincerely, PRIME MEDICINE, INC. /s/ Keith Gottesdiener Keith Gottesdiener President and Chief Executive Officer cc: Allan Reine, Prime Medicine, Inc. Kingsley L. Taft, Goodwin Procter LLP Marishka DeToy, Goodwin Procter LLP